GO VERTICAL ICMWOMEN’S HEALTH COMMUNITY AWARD 2026

 

Meet the innovation

Curiva

Cervical cancer risk stratification, one patch at a time.

Curiva is developing diaPatch™, a non-invasive wearable diagnostic patch designed to support cervical cancer risk stratification and triage after an abnormal Pap smear, before colposcopy.

Cervical healthDiagnostic deviceChicago & Goshen, United States

Support Curiva →

FocusCervical cancer risk stratification
Development statusProduct in development; currently fundraising
Voting periodOctober 1–December 31, 2026

Why it matters

Abnormal screening should lead to clarity sooner.

Curiva identifies a gap in the clinical decision window after an abnormal Pap smear. Patients may face delays, anxiety and additional follow-up before receiving a clearer risk picture.

Its proposed approach is designed to give clinicians an adjunctive, non-invasive option that can support triage before colposcopy and reduce repeat visits and pathway friction.

The proposed solution

diaPatch™ brings sampling and analysis closer to the point of care.

Curiva describes diaPatch™ as a wearable patch combining microneedles-mediated interstitial fluid sampling with a molecular assay for adjunctive cervical risk stratification and triage.

01

Non-invasive collection

The patch is designed to collect interstitial fluid through a wearable, external application rather than relying on an additional invasive procedure.

02

Same-visit workflow

Curiva’s target workflow is designed to support results in under 30 minutes during the clinical visit.

03

Adjunctive triage

The intended use is to support cervical risk stratification after abnormal screening and before a colposcopy follow-up.

04

Human-centered follow-up

The companion ELLEApp™ is described as supporting result delivery and follow-up reminders.

Progress and potential

Building toward a practical cervical-care pathway.

Curiva reports a strong intellectual-property focus, participation in the NSF I-Corps program, membership in innovation and accelerator communities, and active fundraising.

The company’s public materials describe diaPatch™ as under development. Regulatory requirements, clinical validation and product performance remain subject to further evaluation.

This profile summarizes Curiva’s public description of a proposed innovation. Participation in the award is not medical endorsement, clinical validation or regulatory approval.

Stand behind the idea

Support Curiva’s next chapter.

Your paid support backs this entry in the Women’s Health Community Award. Share Curiva’s profile with people working to improve earlier, more accessible cervical cancer care.

Voting is open through December 31, 2026 at 11:59:59 p.m. EST.
Paid support is reconciled manually and community support point totals are updated daily.

Community support point: 1

01 / Choose

Support with US$100

Select your support quantity through the official award checkout. Each US$100 support payment adds one community support point; each point counts as one vote under the Official Rules.

02 / Confirm

Complete checkout

Review the quantity, currency and final total before paying.

03 / Follow

Track the updates

Verified totals and the top-five updates are published during the award period.

Support Curiva with US$100 ↗

Each US$100 support payment adds one community support point to your selected candidate. Each point counts as one vote under the Official Rules. The eligible candidate with the highest valid point total wins, subject to verification and the Official Rules.

Support payments are not donations, investments or credits redeemable for products or services.

What the primary winner receives

Resources for what comes next.

US$5,000–US$25,000

The cash prize starts at US$5,000, with announced increases potentially bringing it to US$25,000, plus a Strategic Discovery Process valued at US$4,800 and recognition through GO Vertical ICM’s network.

Before you support

Does participation establish medical approval?

No. This profile is based on Curiva’s public description of a proposed innovation. Participation is not medical endorsement, clinical validation or regulatory approval.

When does voting close?

December 31, 2026 at 11:59:59 p.m. EST. The winner is announced January 15, 2027 after verification.

Who can help with a payment or missing votes?

Email info@goverticalicm.com with “Curiva,” your payment date and transaction reference. Never send card details or passwords.